---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026241"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:27:29.498257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus ARC-7 Phase 2 data: domvanalimab arms reduce PFS risk 28-33% in NSCLC

## Summary
- Doublet (domvanalimab+zimberelimab) showed 33% PFS risk reduction (HR 0.67) vs zimberelimab monotherapy in PD-L1≥50% NSCLC.
- Median PFS: 5.4 mo (Z), 9.3 mo (DZ), 9.9 mo (EDZ); 12-month PFS rates 25%, 41%, 44%.
- ORR: Z 30%, DZ 40%, EDZ 44%; median DoR not reached for DZ, 23.7 mo for EDZ.
- No unexpected safety signals; infusion-related reactions low (4-12%) across arms.
- Data from 150-patient randomized Phase 2 at ~18-month median follow-up.

## SEC filing metadata
- accession: 0000950170-23-026241
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017023026241/0000950170-23-026241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017023026241/rcus-20230603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026241
- JSON: https://secwatch.observer/filing/0000950170-23-026241.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.